JOSEPH LEWIS
CIK 1015747 · last filed 2024-11-12
JOSEPH LEWIS is a corporate insider who has filed 20 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for INSG, was dated Nov 12, 2024. Across all open-market trades the lifetime net is −$101.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $192.4M across reported positions. 63 SEC filings were submitted jointly with Boxer Capital, LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$192.38M
7
20
-$101.09M
Filer Profile
LEWIS DRIVE
NEW PROVIDENCE N7776
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INSG | 10%+ Owner | 1,800,186 | $4.24 | $7.63M | $58.52M | 10 | 2024-11-12 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 2,946,915 | $10.15 | $29.91M | -$223.71M | 3 | 2024-05-14 |
| TNGX | 10%+ Owner | 8,203,642 | $22.52 | $184.75M | $45.75M | 2 | 2023-10-17 |
| Odonate Therapeutics, Inc. (ODT) Delisted | 10%+ Owner | 4,757,086 | $1.12 | $5.33M | -$6.19M | 1 | 2021-11-19 |
| Carisma Therapeutics Inc. (EBIO) Delisted | 10%+ Owner | 1,390,712 | — | — | -$11.44M | 1 | 2016-06-14 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 522,500 | $58.70 | $30.67M | $38.12M | 2 | 2015-09-18 |
| SOPHIRIS BIO INC. (SPHS) Delisted | 10%+ Owner | 161,447 | — | — | -$2.15M | 1 | 2014-12-17 |
Recent Filings
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-12 | INSG | Other (J) | +1,395,472 | $0 | EDGAR |
| 2024-10-02 | INSG | Grant (A) | +15,310 | $0 | EDGAR |
| 2024-07-02 | INSG | Grant (A) | — | $0 | EDGAR |
| 2024-05-14 | iTeos Therapeutics, Inc. (ITOS) Delisted | Grant (A) | +4,571,428 | $80.00M | EDGAR |
| 2023-10-17 | TNGX | Buy (P) | +6,250,000 | $43.61M | EDGAR |
| 2023-10-03 | INSG | Grant (A) | +431,034 | $0 | EDGAR |
| 2022-10-06 | TNGX | Buy (P) | +546,000 | $2.14M | EDGAR |
| 2022-03-18 | iTeos Therapeutics, Inc. (ITOS) Delisted | Sell (S) | −1,725,603 | -$60.83M | EDGAR |
| 2022-01-05 | iTeos Therapeutics, Inc. (ITOS) Delisted | Sell (S) | −3,500,000 | -$162.88M | EDGAR |
| 2021-11-19 | Odonate Therapeutics, Inc. (ODT) Delisted | Sell (S) | −3,000,000 | -$6.19M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.